Baishakhee Bishoyi, Harshita Jaiswal, Yash Shah, Manoj Dikkatwar, Radhika Bindu
Baishakhee Bishoyi1, Harshita Jaiswal1, Yash Shah1, Manoj Dikkatwar2, Radhika Bindu1*
1Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India.
2Amity Institute of Pharmacy, Amity University, Uttar Pradesh, Lucknow Campus, India.
Volume - 16,
Issue - 5,
Year - 2023
HER 2 positive breast cancers are the aggressive subtype of breast cancer which can be treated completely if early detected. According to the National Cancer Institute, localized or stage 1 female breast cancer patients have a relative survival rate of 99% and they can survive for more than 5 years after diagnosis but only 63.1% cases are diagnosed at this stage. In later stages when it's diagnosed, the relative survival rate becomes 29%. The overexpression of HER2 proteins can be detected by early diagnosis and screening through advanced technologies like 3D mammography, Positron Emission Mammography, Molecular breast imaging, Contrast-enhanced mammography. The specific diagnosis can be done by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) for confirmation of this type of breast cancer. Biomarkers such as Her2 heterogenicity, Her2 expression, Her2 mutations, Hormone receptor (ER positivity, PR positivity), PIK3CA mutation, PTEN, PD-L1, TIL, BRCA, miRNA can be used for detection of breast cancer. With successful early detection, which will be used to diagnose early and start the treatment as early as possible. Recently FDA has approved various individual and combination medications for treating the HER2 positive breast cancer and there are further research studies and clinical trials are going on to get more impactful treatment for providing complete cure of the deadly disease.
Cite this article:
Baishakhee Bishoyi, Harshita Jaiswal, Yash Shah, Manoj Dikkatwar, Radhika Bindu. Early detection and Advanced Targeted Drug Therapies for HER2 positive breast cancer. Research Journal of Pharmacy and Technology 2023; 16(5):2205-9. doi: 10.52711/0974-360X.2023.00362
Baishakhee Bishoyi, Harshita Jaiswal, Yash Shah, Manoj Dikkatwar, Radhika Bindu. Early detection and Advanced Targeted Drug Therapies for HER2 positive breast cancer. Research Journal of Pharmacy and Technology 2023; 16(5):2205-9. doi: 10.52711/0974-360X.2023.00362 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-5-21
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338
3. India-Global Cancer Observatory, GLOBOCAN 2020 [Internet] Available from https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
4. Breast cancer [Internet] Available from https://www.breastcancerindia.net/
5. Padmaja A, Mohanasundari S K, Munuswamy, Murali, K. Sesha Kumar. Evaluate The effectiveness of Awareness programme with health Education on breast cancer and skill Training on breast self-Examination among rural women in chittoor Dist Andhra Pradesh-A Collaborative Research. Asian J. Nursing Education and Research. 2020; 10(1):97-102
6. Lakshmi K. M.1, Jaseela K. T., Anjana P, Ayisha Sithara M. T. Dhrishya. Assess the awareness regarding Early Identification, Prevention and Management of Breast Cancer among Early Adult Women. Asian J. Nursing Education and Research. 2019; 9(1):04-08.
7. Remal Abdulaziz Asaad, Siraj Saadaldin Abdullah. Breast Cancer Subtypes (BCSs) Classification according to Hormone Receptor Status: Identification of patients at High Risk in Jableh- Syria. Research J. Pharm. and Tech. 2018; 11(8): 3703-3710.
8. Breast cancer status [Internet] 2020 [Cited October 03, 2021]. Available fromhttps://www.breastcancer.org/symptoms/diagnosis/her2.
9. Breast cancer risk factors [internet] 2021.Available from https://www.cdc.gov/cancer/breast/basic_info/risk_factors.html
10. Raji Varughese, Shambhavi. Assessment of the Factors Associated with Breast Cancer Screening among Rural Women in Selected Villages, Mangalore. Int. J. Nur. Edu. and Research. 3(2): April-June, 2015; Page 218-223
11. M. Geetha, K. Menaka, P. Padmavathi. Awareness of Breast self-examination and risk factors of Breast Cancer among Women. Asian J. Nur. Edu. and Research. 2017; 7(3): 413-416.
12. Lakshmi K. M.1, Jaseela K. T., Anjana P, Ayisha Sithara M. T. Dhrishya. Assess the awareness regarding Early Identification, Prevention and Management of Breast Cancer among Early Adult Women. Asian J. Nursing Education and Research. 2019; 9(1):04-08.
13. Breast Cancer [Internet] 2021 [cited September 27, 2021]. Available from https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
14. V. N. Dange, S. J. Shid, C.S. Magdum, S.K. Mohite. A Review on Breast Cancer: An Overview. Asian J. Pharm. Res. 2017; 7(1): 49-51
15. Arjun Patidar, S.C.Shivhare, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. & Research. 2012; 2(1): Jan.-March Page 28-32
16. Madhu S, Sathish D K, Vinay Kumar G. A Study to assess the knowledge, attitude and practice regarding Breast Cancer screening among Women in reproductive age (15-45 years) in selected rural areas of Chamarajanagar district with a view to develop educational programme. International Journal of Advances in Nursing Management. 2021; 9(4):367-2.
17. NCI supported research programs [Internet]Available from https://www.cancer.gov/types/breast/research
18. Breast cancer early detection and diagnosis [Internet] Available from https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection.html
19. Klocker E, V, Suppan C: Biomarkers in Her2- Positive Disease. Breast Care 2020;15:586-593. doi: 10.1159/000512283
20. Pushpa A. Karale, Mahesh A. Karale, Mokshada C. Utikar. Advanced Molecular Targeted Therapy in Breast Cancer. Res. J. Pharmacology and Pharmacodynamics. 2018; 10(1): 29-37
21. Perkey, Cassandra PharmD, BCOP Pertuzumab/ Trastuzumab/ Hyaluronidase-Zzxf (Phesgo™), Oncology Times: September 20, 2021 - Volume 43 - Issue 18 - p 6,17 doi: 10.1097/01.COT.0000793152.95554.b5
22. Product Information: PHESGO(TM) subcutaneous injection, pertuzumab, trastuzumab, hyaluronidase-zzxf subcutaneous injection. Genentech Inc (per manufacturer), South San Francisco, CA, 2020.
23. Fam-trastuzumab deruxtecan-nxki [Internet] 2019 [Cited September 27, 2021]. Available from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer.
24. Product Information: ENHERTU(R) intravenous injection, fam-trastuzumab deruxtecan-nxki intravenous injection. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2019.
25. Tucatinib [Internet] 2020 [Cited September 28, 2021]. Available from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer.
26. Product Information: TUKYSA(TM) oral tablets, tucatinib oral tablets. Seattle Genetics Inc (per FDA), Bothell, WA, 2020.
27. Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. Asian J. Res. Pharm. Sci. 2020; 10(2):100-102.
28. Neratinib Maleate[Internet] 2020 [cited October 01, 2021]. Available from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer.
29. Product Information: NERLYNX(TM) oral tablets, neratinib oral tablets. Puma Biotechnology, Inc (per FDA), Los Angeles, CA, 2017.
30. Ado-trastuzumab emtansine (Kadcyla) [Internet] 2019 [cited October 01, 2021]. Available fromhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer.
31. Product Information: KADCYLA(TM) intravenous injection solution, ado-trastuzumab emtansine intravenous injection solution. Genentech, Inc. (per FDA), South San Francisco, CA, 2013.